Immuneering Presents New Genetic Data at AACR Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Should l Buy IMRX?
Immuneering announced the presentation of new genetic data at the 2026 American Association for Cancer Research, AACR, Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Key Findings from the AACR Presentation: Rare MAPK pathway reactivation: Across 86 patients treated with atebimetinib monotherapy and 37 patients treated in combination with chemotherapy, emergent and acquired mutations rarely converged on the RAS/MAPK pathway, in contrast to what is commonly observed with chronic RAS-targeted therapies. Diffuse, non-convergent resistance patterns: Emergent resistance following atebimetinib treatment utilized a variety of non-MAPK pathways, rather than converging on a single escape mechanism. Limited early adaptive resistance: ctDNA analysis showed minimal early molecular evolution during treatment, indicating that atebimetinib is not driving adaptive resistance and may impose less selective pressure than continuous pathway inhibition. Taken together, the data position atebimetinib as a differentiated MEK inhibitor with potential to drive deep and durable antitumor activity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMRX
Wall Street analysts forecast IMRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.140
Low
11.00
Averages
14.50
High
20.00
Current: 5.140
Low
11.00
Averages
14.50
High
20.00
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immuneering Q1 Earnings Beat Expectations
- Earnings Beat: Immuneering reported a Q1 GAAP EPS of -$0.21, exceeding market expectations by $0.04, indicating some resilience in financial performance despite ongoing losses.
- Cash Position Decline: As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $198.6 million, down from $217.0 million as of December 31, 2025, reflecting operational expenditure pressures.
- Optimistic Financial Guidance: Based on the cash position as of March 31, 2026, and current operational plans, the company expects its cash runway to be sufficient to fund operations into 2029, demonstrating confidence in financial management.
- Increased Market Attention: Following the earnings release, Immuneering's market attention has risen, with Seeking Alpha's Quant Rating expressing optimism about the company's future, potentially attracting more investor interest.
See More
Immuneering Reports New Data on Pancreatic Cancer Clinical Trials
- Clinical Trial Progress: Immuneering will present survival data from 55 first-line pancreatic cancer patients at the 2026 ASCO Annual Meeting, which is expected to further propel the clinical application of atebimetinib combined with mGnP, enhancing the company's market position in oncology.
- Key Trial Recruitment: The MAPKeeper 301 trial is now recruiting patients to evaluate the efficacy of atebimetinib with mGnP, with the first patient dosing expected to begin by mid-2026, marking a strategic move in the pancreatic cancer treatment landscape.
- Patient Survival Data: A third-line pancreatic cancer patient treated with atebimetinib monotherapy for 27 months has shown an 85% reduction in tumor burden, highlighting the drug's potential to extend survival and improve quality of life, which may provide critical insights for future treatment protocols.
- Strong Financial Position: As of Q1 2026, Immuneering reported $198.6 million in cash and cash equivalents, with an anticipated runway into 2029, demonstrating the company's ongoing investment capability in R&D and market expansion.
See More
Immuneering Presents Promising Data for Cancer Drug Atebimetinib
- Clinical Trial Data: Immuneering Corporation presented clinical trial data for its cancer drug Atebimetinib at the American Association of Cancer Research annual meeting, involving 123 patients, with 86 on monotherapy and 37 on combination therapy, indicating the drug's potential in anti-tumor activity.
- Resistance Mechanism Analysis: The data revealed that acquired mutations in tumor cells during treatment primarily occurred in non-MAPK pathways, suggesting that Atebimetinib may provide more durable effects in inhibiting tumor cell proliferation, potentially leading to longer survival for patients.
- Key Trial Progress: The company anticipates initiating the pivotal Phase 3 MAPKeeper 301 trial by mid-2026 to evaluate the efficacy of Atebimetinib combined with modified Gemcitabine/nab-Paclitaxel in treating first-line metastatic pancreatic cancer patients.
- Future Trial Plans: Immuneering also plans to begin a Phase 2 trial for Atebimetinib in the second half of this year, targeting first-line RAS-mutant non-small cell lung cancer patients, further validating its clinical application potential.
See More
Atebimetinib Shows Promising Results in Tumor Treatment
- Rare Resistance Mechanisms: Among 123 patients treated with atebimetinib, very few exhibited MAPK pathway mutations commonly associated with RAS inhibitors, indicating lower resistance in first-line treatment and enhancing its clinical application potential.
- Diverse Resistance Patterns: In 86 patients receiving monotherapy and 37 patients undergoing combination therapy, resistance mechanisms did not converge on the RAS/MAPK pathway but instead displayed a variety of non-MAPK pathways, showcasing atebimetinib's unique anti-tumor mechanisms.
- Limited Early Adaptive Resistance: ctDNA analysis revealed minimal early molecular evolution during treatment, suggesting that atebimetinib imposes less selective pressure, potentially improving treatment durability by reducing adaptive resistance.
- Clinical Trial Progress: Immuneering expects to initiate its pivotal MAPKeeper 301 Phase 3 trial in mid-2026, evaluating the efficacy of atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer, further validating its clinical value.
See More
Immuneering Reports Q4 EPS Beat with Strong Cash Position
- Earnings Highlights: Immuneering reported a Q4 GAAP EPS of -$0.18, beating expectations by $0.13, indicating resilience in financial performance despite a challenging market environment.
- Strong Cash Reserves: As of 2025, Immuneering holds $217 million in cash, cash equivalents, and marketable securities, with an anticipated runway extending into 2029, ensuring operational stability for the coming years.
- Clinical Trial Progress: The company reported a positive 12-month overall survival update from the Phase IIa trial of Atebimetinib for pancreatic cancer, demonstrating potential therapeutic value despite a stock price decline due to data volatility.
- Nasdaq Biotechnology Index Inclusion: Immuneering's addition to the Nasdaq Biotechnology Index signifies increased recognition within the industry, potentially attracting more investor interest in its future developments.
See More
IMMUNEERING CORP SET TO RELEASE EXPANDED PANCREATIC CANCER COHORT DATA IN EARLY 2026
Immuneering Corp Update: Immuneering Corp is on track for an expanded pancreatic cancer cohort data readout scheduled for the first half of 2026.
Focus on Cancer Research: The company is emphasizing its commitment to advancing research in pancreatic cancer through its innovative approaches.
See More
Immuneering Q1 Earnings Beat Expectations
- Earnings Beat: Immuneering reported a Q1 GAAP EPS of -$0.21, exceeding market expectations by $0.04, indicating some resilience in financial performance despite ongoing losses.
- Cash Position Decline: As of March 31, 2026, the company's cash, cash equivalents, and marketable securities totaled $198.6 million, down from $217.0 million as of December 31, 2025, reflecting operational expenditure pressures.
- Optimistic Financial Guidance: Based on the cash position as of March 31, 2026, and current operational plans, the company expects its cash runway to be sufficient to fund operations into 2029, demonstrating confidence in financial management.
- Increased Market Attention: Following the earnings release, Immuneering's market attention has risen, with Seeking Alpha's Quant Rating expressing optimism about the company's future, potentially attracting more investor interest.
See More
Immuneering Reports New Data on Pancreatic Cancer Clinical Trials
- Clinical Trial Progress: Immuneering will present survival data from 55 first-line pancreatic cancer patients at the 2026 ASCO Annual Meeting, which is expected to further propel the clinical application of atebimetinib combined with mGnP, enhancing the company's market position in oncology.
- Key Trial Recruitment: The MAPKeeper 301 trial is now recruiting patients to evaluate the efficacy of atebimetinib with mGnP, with the first patient dosing expected to begin by mid-2026, marking a strategic move in the pancreatic cancer treatment landscape.
- Patient Survival Data: A third-line pancreatic cancer patient treated with atebimetinib monotherapy for 27 months has shown an 85% reduction in tumor burden, highlighting the drug's potential to extend survival and improve quality of life, which may provide critical insights for future treatment protocols.
- Strong Financial Position: As of Q1 2026, Immuneering reported $198.6 million in cash and cash equivalents, with an anticipated runway into 2029, demonstrating the company's ongoing investment capability in R&D and market expansion.
See More
Immuneering Presents Promising Data for Cancer Drug Atebimetinib
- Clinical Trial Data: Immuneering Corporation presented clinical trial data for its cancer drug Atebimetinib at the American Association of Cancer Research annual meeting, involving 123 patients, with 86 on monotherapy and 37 on combination therapy, indicating the drug's potential in anti-tumor activity.
- Resistance Mechanism Analysis: The data revealed that acquired mutations in tumor cells during treatment primarily occurred in non-MAPK pathways, suggesting that Atebimetinib may provide more durable effects in inhibiting tumor cell proliferation, potentially leading to longer survival for patients.
- Key Trial Progress: The company anticipates initiating the pivotal Phase 3 MAPKeeper 301 trial by mid-2026 to evaluate the efficacy of Atebimetinib combined with modified Gemcitabine/nab-Paclitaxel in treating first-line metastatic pancreatic cancer patients.
- Future Trial Plans: Immuneering also plans to begin a Phase 2 trial for Atebimetinib in the second half of this year, targeting first-line RAS-mutant non-small cell lung cancer patients, further validating its clinical application potential.
See More
Atebimetinib Shows Promising Results in Tumor Treatment
- Rare Resistance Mechanisms: Among 123 patients treated with atebimetinib, very few exhibited MAPK pathway mutations commonly associated with RAS inhibitors, indicating lower resistance in first-line treatment and enhancing its clinical application potential.
- Diverse Resistance Patterns: In 86 patients receiving monotherapy and 37 patients undergoing combination therapy, resistance mechanisms did not converge on the RAS/MAPK pathway but instead displayed a variety of non-MAPK pathways, showcasing atebimetinib's unique anti-tumor mechanisms.
- Limited Early Adaptive Resistance: ctDNA analysis revealed minimal early molecular evolution during treatment, suggesting that atebimetinib imposes less selective pressure, potentially improving treatment durability by reducing adaptive resistance.
- Clinical Trial Progress: Immuneering expects to initiate its pivotal MAPKeeper 301 Phase 3 trial in mid-2026, evaluating the efficacy of atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer, further validating its clinical value.
See More
Immuneering Reports Q4 EPS Beat with Strong Cash Position
- Earnings Highlights: Immuneering reported a Q4 GAAP EPS of -$0.18, beating expectations by $0.13, indicating resilience in financial performance despite a challenging market environment.
- Strong Cash Reserves: As of 2025, Immuneering holds $217 million in cash, cash equivalents, and marketable securities, with an anticipated runway extending into 2029, ensuring operational stability for the coming years.
- Clinical Trial Progress: The company reported a positive 12-month overall survival update from the Phase IIa trial of Atebimetinib for pancreatic cancer, demonstrating potential therapeutic value despite a stock price decline due to data volatility.
- Nasdaq Biotechnology Index Inclusion: Immuneering's addition to the Nasdaq Biotechnology Index signifies increased recognition within the industry, potentially attracting more investor interest in its future developments.
See More
IMMUNEERING CORP SET TO RELEASE EXPANDED PANCREATIC CANCER COHORT DATA IN EARLY 2026
Immuneering Corp Update: Immuneering Corp is on track for an expanded pancreatic cancer cohort data readout scheduled for the first half of 2026.
Focus on Cancer Research: The company is emphasizing its commitment to advancing research in pancreatic cancer through its innovative approaches.
See More
